260 related articles for article (PubMed ID: 36613550)
1. Targeting the Isoprenoid Biosynthetic Pathway in Multiple Myeloma.
Haney SL; Holstein SA
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613550
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Dykstra KM; Allen C; Born EJ; Tong H; Holstein SA
Oncotarget; 2015 Dec; 6(39):41535-49. PubMed ID: 26595805
[TBL] [Abstract][Full Text] [Related]
3. Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.
Holstein SA; Hohl RJ
Leuk Res; 2011 Apr; 35(4):551-9. PubMed ID: 20828814
[TBL] [Abstract][Full Text] [Related]
4. In vivo evaluation of combination therapy targeting the isoprenoid biosynthetic pathway.
Haney SL; Varney ML; Chhonker Y; Talmon G; Smith LM; Murry DJ; Holstein SA
Pharmacol Res; 2021 May; 167():105528. PubMed ID: 33667685
[TBL] [Abstract][Full Text] [Related]
5. The intermediate enzymes of isoprenoid metabolism as anticancer targets.
Wiemer AJ; Hohl RJ; Wiemer DF
Anticancer Agents Med Chem; 2009 Jun; 9(5):526-42. PubMed ID: 19519294
[TBL] [Abstract][Full Text] [Related]
6. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.
Henneman L; van Cruchten AG; Kulik W; Waterham HR
Biochim Biophys Acta; 2011 Apr; 1811(4):227-33. PubMed ID: 21237288
[TBL] [Abstract][Full Text] [Related]
8. Differential activities of thalidomide and isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Holstein SA; Tong H; Hohl RJ
Leuk Res; 2010 Mar; 34(3):344-51. PubMed ID: 19646757
[TBL] [Abstract][Full Text] [Related]
9. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
Wiemer AJ; Yu JS; Shull LW; Barney RJ; Wasko BM; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Apr; 16(7):3652-60. PubMed ID: 18308574
[TBL] [Abstract][Full Text] [Related]
10. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.
Reilly JE; Neighbors JD; Tong H; Henry MD; Hohl RJ
Clin Exp Metastasis; 2015 Aug; 32(6):555-66. PubMed ID: 26070429
[TBL] [Abstract][Full Text] [Related]
11. Protein prenylation: unique fats make their mark on biology.
Wang M; Casey PJ
Nat Rev Mol Cell Biol; 2016 Feb; 17(2):110-22. PubMed ID: 26790532
[TBL] [Abstract][Full Text] [Related]
12. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Wiemer AJ; Tong H; Swanson KM; Hohl RJ
Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Small GTPase Prenylation in the Nervous System.
Reddy JM; Raut NGR; Seifert JL; Hynds DL
Mol Neurobiol; 2020 May; 57(5):2220-2231. PubMed ID: 31989383
[TBL] [Abstract][Full Text] [Related]
14. ω-Hydroxy isoprenoid bisphosphonates as linkable GGDPS inhibitors.
Bhuiyan NH; Varney ML; Bhattacharya DS; Payne WM; Mohs AM; Holstein SA; Wiemer DF
Bioorg Med Chem Lett; 2019 Oct; 29(19):126633. PubMed ID: 31474482
[TBL] [Abstract][Full Text] [Related]
15. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Wiemer AJ; Yu JS; Lamb KM; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2008 Jan; 16(1):390-9. PubMed ID: 17905588
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Evaluation of Isoprenoid Triazole Bisphosphonate Inhibitors of Geranylgeranyl Diphosphate Synthase: Impact of Olefin Stereochemistry on Toxicity and Biodistribution.
Haney SL; Chhonker YS; Varney ML; Talmon G; Smith LM; Murry DJ; Holstein SA
J Pharmacol Exp Ther; 2019 Nov; 371(2):327-338. PubMed ID: 31420526
[TBL] [Abstract][Full Text] [Related]
17. Statins inhibited the MIP-1α expression via inhibition of Ras/ERK and Ras/Akt pathways in myeloma cells.
Tsubaki M; Mashimo K; Takeda T; Kino T; Fujita A; Itoh T; Imano M; Sakaguchi K; Satou T; Nishida S
Biomed Pharmacother; 2016 Mar; 78():23-29. PubMed ID: 26898421
[TBL] [Abstract][Full Text] [Related]
18. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
19. Anti-cancer therapy: targeting the mevalonate pathway.
Swanson KM; Hohl RJ
Curr Cancer Drug Targets; 2006 Feb; 6(1):15-37. PubMed ID: 16475974
[TBL] [Abstract][Full Text] [Related]
20. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.
Oldfield E
Acc Chem Res; 2010 Sep; 43(9):1216-26. PubMed ID: 20560544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
